Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2798175 | 0.98 | EPHX1 (0.44) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| Hydrochloric Acid SCHEMBL2794765 | 0.98 | EPHX1 (0.44) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| Trifluoroacetic Acid SCHEMBL29191950 | 0.94 | CHRM2 (0.44) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL13397666 | 0.92 | CHRM2 (0.43) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL4634900 | 0.89 | EPHX1 (0.41) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL4634897 | 0.89 | EPHX1 (0.41) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL5511542 | 0.89 | EPHX1 (0.41) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| Hydrochloric Acid SCHEMBL4635025 | 0.88 | EPHX1 (0.40) | EPHX1CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL5758149 | 0.80 | EPHX1 (0.46) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL28278914 | 0.79 | GAA (0.51) | EPHX1CHRM1EPHX2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311850-B | Imidazolone compounds as human neutrophil elastase inhibitors | 奇斯药制品公司 | 2021-11-19 | — | — | CN | claimed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | claimed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | claimed |
| CN-109311850-A | Imidazoquinolone compounds as people's inhibitors of neutrophil elastase | 奇斯药制品公司 | 2019-02-05 | — | — | CN | claimed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | claimed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| US-10882854-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-01-05 | — | — | US | disclosed |
| US-10882854-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-01-05 | — | — | US | disclosed |
| EP-3197885-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2020-11-18 | — | — | EP | disclosed |
| EP-3197885-B1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2020-11-18 | — | — | EP | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| US-20040242637-A1 | Tyrosine kinase inhibitors | HARTMAN GEORGE D (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2003015717-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | EPHX1 110/4885CHRM2 4619/4885CHRM1 4648/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885CHRM2 3492/4885CHRM1 3759/4885 |
| US-20040242637-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | EPHX1 2048/4885CHRM2 4663/4885CHRM1 4624/4885 |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | EPHX1 1481/4885CHRM2 1756/4885CHRM1 920/4885 |
| US-10882854-B2 | Heterocyclic compounds and use thereof | CXCL12, HPGDS, CX3CR1 | EPHX1 76/4885CHRM2 2674/4885CHRM1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.